Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Author information

Affiliations

  • 1. Department of Medical Oncology, Medical Oncology Unit 1, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.
      Authors
    • Gelsomino F 1
    • Gelsomino F 1
    • Haspinger ER 1
    • Garassino MC 1
    • De Braud F 1
    (5 authors)
  • 2. Medical Oncology Unit, University Hospital of Parma, Italy.
      Authors
    • Facchinetti F 2
    • Tiseo M 2
    (2 authors)
  • 3. Laboratory of Molecular Pharmacology, Institute for Cancer Research and Treatment, and Department of Oncological Sciences, University of Torino School of Medicine, Candiolo (Torino), Italy.
      Authors
    • Trusolino L 3
    (1 author)

ORCIDs linked to this article

Show all (6)

Critical Reviews in Oncology/hematology, 01 Dec 2013, 89(2):284-299
https://doi.org/10.1016/j.critrevonc.2013.11.006 PMID: 24355409 

Review

Abstract 

Recently, a better understanding of the specific mechanisms of oncogene addiction has led to the development of antitumor strategies aimed at blocking these abnormalities in different malignancies, including lung cancer. These abnormalities trigger constitutive activation of tyrosine kinase receptors (RTKs) involved in fundamental cell mechanisms such as proliferation, survival, differentiation and migration, and consequently the aberrant signaling of RTKs leads to cancer growth and survival. The inhibition of aberrant RTKs and downstream signaling pathways has opened the door to the targeted therapy era. In non-small-cell lung cancer (NSCLC), molecular research has allowed the discrimination of different aberrant RTKs in lung cancer tumorigenesis and progression, and thus the identification of several targetable oncogenic drivers. Following the development of small molecules (gefitinib/erlotinib and crizotinib) able to reversibly inhibit the epidermal growth factor receptor (EGFR) and signaling pathways mediated by anaplastic lymphoma kinase (ALK), respectively, the MET signaling pathway has also been recognized as a potential target. Moreover, according to current knowledge, MET could be considered both as a secondary oncogenic mechanism and as a prognostic factor. Several therapeutic strategies for inhibiting activated hepatocyte growth factor receptor (HGFR) and the subsequent downstream signaling transduction have been improved in order to block tumor growth. This review will focus on the MET pathway and its role in resistance to EGFR TK (tyrosine kinase) inhibitors, the different strategies of its inhibition, and the potential approaches to overcoming acquired resistance.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.critrevonc.2013.11.006

References 

Articles referenced by this article (142)

Show 10 more references (10 of 142)

Citations & impact 

Impact metrics

55
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/2256426
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/2256426

Article citations

Go to all (55) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.